Vlado Perkovic's Publications

• Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.

  Journal articles

  2025

  N Engl J Med

• Effects of Semaglutide on CKD in Patients With Type 2 Diabetes

  Journal articles

  2025

  Kidney International Reports

• Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomised control trials

  Journal articles

  2025

  Clinical Kidney Journal

• Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials

  Journal articles

  2025

  European Journal of Heart Failure

• Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

  Journal articles

  2025

  Diabetes, Obesity and Metabolism

• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

  Journal articles

  2025

  The Lancet Diabetes and Endocrinology

• The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system

  Journal articles

  2025

  Peritoneal Dialysis International

• Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD

  Journal articles

  2025

  Kidney International Reports

• WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mLMIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS

  Journal articles

  2025

  Kidney International Reports

• WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK

  Journal articles

  2025

  Kidney International Reports

• WCN25-1567 Glomerular disease registry and Biobank (GRIT) design and baseline results

  Journal articles

  2025

  Kidney International Reports

• WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY

  Journal articles

  2025

  Kidney International Reports

• WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY

  Journal articles

  2025

  Kidney International Reports

• WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY

  Journal articles

  2025

  Kidney International Reports

• WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE

  Journal articles

  2025

  Kidney International Reports

• WCN25-1900 Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial

  Journal articles

  2025

  Kidney International Reports

• The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial.

  Journal articles

  2024

  Kidney Int

• The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol

  Journal articles

  2024

  JAMA network open

• Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes

  Journal articles

  2024

  Journal of the American College of Cardiology

• Cardiovascular, Kidney, and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

  Journal articles

  2024

  Circulation

• Semaglutide for Chronic Kidney Disease in Type 2 Diabetes. Reply

  Journal articles

  2024

  The New England journal of medicine

• Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS

  Journal articles

  2024

  European Heart Journal

• Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  European Heart Journal

• Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial

  Journal articles

  2024

  Journal of the American College of Cardiology

• Canagliflozin and iron metabolism in the CREDENCE trial

  Journal articles

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION